biomarkers

Seven diseases benefiting from genetic tests
Seven diseases benefiting from genetic testsGenetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.
Latest research brings awareness to new AMD discoveriesResearch on treatments and/or causes of age-related macular degeneration (AMD) covers a wide range of approaches and paradigms. The latest research published in the past three months are perfect examples for understanding and treating AMD.
Novel biomarker accurately identifies infants with UTIsUrinary neutrophil gelatinase-associated lipocalin (uNGAL) is highly sensitive and specific for diagnosing urinary tract infections (UTIs), according to a study in febrile children aged up to 24 months.
Study: Racial disparity in breast cancer mortality, ratesA new report from The American Cancer Society shows that in every US state, breast cancer incidence rates are higher in non-Hispanic white (NHW) women than in non-Hispanic black (NHB) women, but rates of death from the disease, however, are higher in NHB women than in NHW women. Also: Is second-stage labor longer with epidural analgesia? Plus, a study finds that ovarian reserve biomarkers are not associated with fertility.
Personalized medicine brings big wins to managed careA new report reveals how personalized medicine can make patients healthier while lowering costs.
New strategies for managing drug spend: RA, Cancer, Hep C
New strategies for managing drug spend: RA, Cancer, Hep CThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow.
Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Genetic testing: Two downsides to considerGenetic testing holds great promise, but there are some critical drawbacks to consider.
Top barriers to fully utilizing precision medicine biomarkersAs development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care—and discussing how to efficiently share the massive amounts of genomic data that will result.
Top 10 sessions to attend at ASH 2016This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.